360° Coverage : Novel Genetic Test for Breast Cancer May Guide MRI Screening In...

1 Updates
Novel Genetic Test for Breast Cancer May Guide MRI Screening In Women With Intermediate Lifetime Risk
Photo Credit: Forbes Business

Novel Genetic Test for Breast Cancer May Guide MRI Screening In Women With Intermediate Lifetime Risk

Dec 20 2013, 1:24am CST | by

Researchers from Archimedes Inc., a healthcare modeling and analytics company, have reported the findings of a simulated clinical trial, “Cost-Effectiveness Of A Genetic Test For Breast Cancer Risk...

Filed under: news


35 weeks ago

Novel Genetic Test for Breast Cancer May Guide MRI Screening In Women With Intermediate Lifetime Risk

Dec 20 2013, 1:24am CST | by

Researchers from Archimedes Inc., a healthcare modeling and analytics company, have reported the findings of a simulated clinical trial, “Cost-Effectiveness Of A Genetic Test For Breast Cancer Risk,” which demonstrated that the seven single-nucleotide polymorphisms (7SNP) genetic test by BREVAGen TM for breast cancer was most cost effective when utilized for MRI screenings in patients found to have an intermediate lifetime risk of developing the disease.

The research was published December 5th online in the Journal, Cancer Prevention Research.

“This Archimedes Model simulation suggests that genetic screening for breast cancer risk in conjunction with MRI can reduce cancer deaths and identifies a population at an intermediate risk near 20 percent for which it is optimally cost effective,” said Tuan Dinh, PhD, vice president of analytics and modeling at Archimedes and one of the authors of study. “This study further illustrates that risk modeling may provide information that will enable physicians to better determine a patient’s risk of disease and more appropriately allocate resources that will be beneficial.”

The American Cancer Society in 2007 recommended MRI as an adjunct to mammography for the screening of breast cancer in women who have a lifetime risk of breast cancer of approximately 20-25 percent or greater as predicted by models such as the Gail test which evaluate family history and other key factors in a woman’s reproductive history.

In the simulated trial, investigators used Archimedes’ simulation model of breast cancer risk factors, disease progression, and healthcare processes to estimate the costs and benefits of using genetic testing to focus estimates of risk for the goal of referring women to MRI screening. The simulation first evaluated screening and treatment, but also growth, detection, and spread of tumors.

The Archimedes model examined and compared two tests, the Gail risk test and the 7SNP test, to organize patients according to lifetime risk.  The Gail model, used by the National Cancer Institute (NCI) and most widely employed overall, estimates risk using information on age, race, family history, and age of menarche and first live birth. The 7SNP genetic test uses the genotype or genetic make-up of the patient to clarify and refine the estimate of the Gail test. In the simulated study, average-risk patients received an annual mammogram and high-risk patients received an annual MRI.

According to Dr. Lucy Langer, Medical Director of the Compass Oncology Genetic Risk Evaluation and Testing Program (G.R.E.A.T.) and the National Medical Director and co-founder of US Oncology Cancer Genetics, the BREVAGen genetic test “is a germline genetic test looking at 7 single nucleotide polymorphisms (SNP) on 6 different chromosomes”. Langer explains that the SNPs in this study were hand selected out of the literature as likely to impact the estimate of a woman’s risk of breast cancer.

“Each of the individual SNPs by themselves don’t increase risk of breast cancer very significantly, but taken together the combination of SNPs gives a risk score that then can be used to modify the Gail risk calculation”, said Langer. “The test is targeted toward intermediate risk women–women that do not look that they have a hereditary cancer syndrome which would put them into a high risk category”.

The simulated population consisted of 100,000 non-Hispanic white women starting at the age of 40 with no prior history of cancer and a lifetime Gail risk of breast cancer of at least 10 percent. Cancer incidence was based on Surveillance, Epidemiology, and End Results (SEER) data and validated to the Cancer Prevention Study II (CPS-II) Nutrition Cohort dataset. Risk factors were drawn from the National Health and Nutrition Examination Survey (NHANES-4) and Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial data.  Mammogram characteristics were derived from Breast Cancer Surveillance Consortium data.

For patients with a lifetime risk of at least 10 percent, the model demonstrated that the 7SNP test results in a 2.7 percent reduction in cancer deaths relative to the Gail test alone. For patients with a risk of 16-28 percent, the 7SNP test saved 0.005 quality-adjusted life years (QALY) per person at a cost of $163,264 per QALY. The cost effectiveness of using the 7SNP test for patients with intermediate Gail risk is similar to that of other recommended strategies, including annual MRI for patients with a lifetime risk greater than 20 percent for BRCA1/2 mutations, for which the model estimated a cost of $141,415 per QALY, relative to mammogram.

According to Dr. Henri Folse, lead author of the study, “For 40-year old women, genetic screening of patients with a lifetime risk of breast cancer of 16 – 28% is optimally efficient and results in a 2% reduction in breast cancer deaths compared to current guidelines using the Gail test.”

“These findings may help physicians and their patients as they strive to identify optimal breast cancer screening options for individual women based on their current risk profile,” explained Folse.   “While the BREVAGen test is not likely to re-classify people with very low or high risk, for patients with intermediate risk it can refine risk classification, which reduces cancer mortality and is equivalently cost-effective to the use of the Gail test with MRI.”

“Investigators can use mathematical modeling and cost-effectiveness analyses, such as those described in this study, to identify an optimal range of risk for which prevention and screening strategies are most cost effective,” said Folse .

“By improving identification of patients eligible for MRI screening, the use of genetic testing allows physicians to detect cancers earlier, which improves prognosis and has the potential to save lives”, Folse concluded.

This study was a collaborative project between Archimedes and Genetic Technologies Ltd./>/>

Genetic Technologies Ltd, with offices in Australia and the US, is a diagnostics company with two decades of experience in commercializing genetic testing, as well as product patenting and non-coding DNA. Genetic Technologies is focused on the commercialization of its patent portfolio through an active out-licensing program and the global expansion of its oncology and cancer management diagnostics assets. Phenogen’s lead product, BREVAGen is a clinically validated risk assessment , and first in class assay for evaluation of non-familial or sporadic breast cancer. Phenogen Sciences Inc., its US subsidiary, markets unique assessment tools and predictive assays evaluation of women’s health.

Source: Forbes Business


1 hour ago

MAS posts loss of RM307m for Q2

Aug 28 2014 5:00pm CDT | Source: Business Times Singapore

August 29, 2014 1:13 AMMALAYSIA Airlines (MAS) registered a loss of RM307 million (S$122 million) for the second quarter to end-June, but warned of worse to come in the second half when the "full financial impact of the double tragedies of MH370 ...
Source: Business Times Singapore   Full article at: Business Times Singapore


Don't miss ...


<a href="/latest_stories/all/all/30" rel="author">Forbes</a>
Forbes is among the most trusted resources for the world's business and investment leaders, providing them the uncompromising commentary, concise analysis, relevant tools and real-time reporting they need to succeed at work, profit from investing and have fun with the rewards of winning.


blog comments powered by Disqus

Latest stories

Human trials of Ebola vaccine to start next week
Washinton, Aug 29 (IANS) The US government announced Thursday that it will start initial human trials of Ebola vaccine next week.
4,000 Gaza fishermen go fishing in six-mile area
Gaza, Aug 28 (IANS) As many as 4,000 fishermen in the Gaza Strip Thursday were able to go fishing in a expanded zone, previously restricted to just three miles by Israel, a senior Palestinian official said.
Number of Ebola cases may reach 20,000: WHO
Geneva, Aug 28 (IANS/EFE) The number of people infected with the Ebola virus in Western Africa could reach 20,000, six times more than the current estimates, the World Health Organisation (WHO) warned Thursday.
Trim down your 'side fat'
Los Angeles, Aug 28 (IANS) Eliminate that extra padding on the sides of your waist by doing the right moves, eating well and moving around.

Latest from the Network

Obama says mulling options against Islamic State
Washington, Aug 29 (IANS) US President Barack Obama said Thursday he has asked his administration to prepare a range of military options against the Islamic State (IS) militants in Iraq and Syria. At a press...
Read more on Politics Balla
Miley Cyrus invites Jesse Held to live with her
London, Aug 29 (IANS) Pop star Miley Cyrus is currently living with her homeless friend Jesse Held, whom she recently took to the MTV Video Music Awards. The "Wrecking Ball" singer shocked onlookers at the music...
Read more on Celebrity Balla
Over 50,000 remain in shelters in Gaza
United Nations, Aug 29 (IANS) At least 54,000 people still remained in 78 United Nations Relief and Works Agency (UNRWA) shelters in Gaza Strip, a UN official said. Stephane Dujarric, a UN spokesman, said at a daily...
Read more on Politics Balla
Jon Voight not invited to Angelina Jolie's wedding?
Jon Voight reportedly wasn't invited to Angelina Jolie and Brad Pitt's wedding last weekend. The 75-year-old actor allegedly wasn't aware that his daughter, whom he was estranged from for several years but reconciled...
Read more on Celebrity Balla
Bobbi Kristina Brown's husband charged with DUI
Bobbi Kristina Brown's husband has been charged with driving under the influence (DUI). Nick Gordon, 25, was arrested this morning (08.28.14) for allegedly drink-driving, failure to maintain a lane and driving with a...
Read more on Celebrity Balla
Christina Aguilera to lose 40lbs in 4 months?
Christina Aguilera wants to lose 40lbs in four months. The 33-year-old singer only gave birth to her daughter Summer Rain two weeks ago but she's reportedly already thinking about getting her pre-baby figure back. A...
Read more on Celebrity Balla
Blake Lively attacked by swarm of bees
Blake Lively was attacked by a swarm of bees last weekend. The 27-year-old actress was left ''swollen'' and ''shaken'' after she was stung by a group of the flying insects while shooting new content for her blog on...
Read more on Celebrity Balla
Alexa Chung may get a face lift?
Los Angeles, Aug 29 (IANS) Model Alexa Chung is worried about her wrinkled skin and says she has considered having a face lift in the future. The 30-year-old, who will turn 31 in November, says she worries about her...
Read more on Celebrity Balla
IS kills 160 Syrian soldiers in Syria: activists
Damascus, Aug 29 (IANS) The Islamic State (IS) militants killed more than 160 Syrian soldiers captured by them in Syria's northern province of al-Raqqa, activists said. The militants captured the Syrian soldiers while...
Read more on Politics Balla
EU to discuss further sanctions against Russia: Merkel
Berlin, Aug 29 (IANS) German Chancellor Angela Merkel announced Thursday that the European Union will discuss further sanctions against Russia on its special summit in Brussels Saturday. "We want diplomatic solutions...
Read more on Politics Balla